Skip to main content
TTRX
NASDAQ Life Sciences

Turn Therapeutics 10-Q: $13.1M Nine-Month Loss, Going Concern, $10.4M Cash Into Q3 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$9.48
Mkt Cap
$289.45M
52W Low
$2.57
52W High
$16.45
52W Position info
269% above low
Off High info
42% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

TTRX has more than doubled off its 52-week low of $2.57.

Summary

Turn Therapeutics' Q3 10-Q shows a $6.2 million quarterly loss driven mostly by a $3.34 million non-cash derivative remeasurement, $10.4 million of cash funding operations into Q3 2027, and a going-concern warning as it lines up a $2.7 million GEM draw-down and an undrawn $8.0 million loan tranche.


Key Events · Earnings and Guidance · TTRX

  • Q3 Loss Widens on Non-Cash Charge

    Net loss was $6.2 million, or $(0.21) per share, versus $1.9 million, or $(0.07), a year earlier. The swing is largely a $3.34 million non-cash loss from change in fair value of a derivative liability instrument — no cash outflow and no new shares issued.

  • Cash Runway Into Q3 2027

    Cash and cash equivalents were $10.4 million at September 30, 2026, against a $35.4 million accumulated deficit. Management expects funding to cover the Phase 2b AD trial and planned Phase 2a HS trial into Q3 2027.

  • Going Concern Warning Reiterated

    The filing states capital resources may not fund operations for at least the next 12 months, raising substantial doubt about the ability to continue as a going concern. The company estimates it needs up to $60 to $65 million for Phase 3 AD and onychomycosis trials plus about $2.5 million for the Phase 2a HS study.

  • GEM Draw-Down and Undrawn Loan Tranche

    On October 29, 2026 the company noticed a draw-down of 272,642 shares to GEM at a $10.00 threshold price, with $2.7 million advanced and the period expected to close November 20, 2026. The Avenue Capital facility's $8.0 million Tranche 2 was undrawn at September 30, 2026, pending Phase 3 dosing, a $10 million equity raise and positive Phase 2 AD data.


Analysis · TTRX · Life Sciences

The headline Q3 loss of $6.2 million versus $1.9 million a year earlier looks alarming, but $3.34 million of that red ink is a non-cash mark-to-market loss on a derivative liability — the warrant and conversion features were remeasured upward as the share price rose, so it reflects neither cash outflow nor new dilution. Operating expenses were essentially flat at $1.98 million, leaving the underlying burn stable. The real constraint is the balance sheet: $10.4 million of cash against a $35.4 million accumulated deficit, with management flagging substantial doubt about continuing as a going concern and estimating it needs $60 to $65 million for Phase 3 AD and onychomycosis trials plus $2.5 million for the HS study. Funding hinges on the GEM equity line — a $2.7 million draw-down noticed October 29, 2026, expected to close November 20, 2026 — and the Avenue Capital loan, where the $8.0 million Tranche 2 remains undrawn pending Phase 3 dosing, a $10 million equity raise and positive Phase 2 AD data. Phase 2b AD topline results are expected in the first quarter of 2027.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TTRX was trading at $9.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $289.5M. The 52-week trading range was $2.57 to $16.45. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TTRX - Latest Insights

TTRX
Nov 09, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.48
Real-time Price: $9.48 info
Change: $0 (0%) info
Market Cap: $289.45M info
TTRX
Nov 09, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $9.48
Real-time Price: $9.48 info
Change: $0 (0%) info
Market Cap: $289.45M info
TTRX
Nov 05, 2026, 8:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $9.80
Real-time Price: $9.48 info
Change: -$0.320 (-3%) info
Market Cap: $289.45M info
TTRX
Oct 06, 2026, 7:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.64
Real-time Price: $9.48 info
Change: -$2.16 (-19%) info
Market Cap: $289.45M info
TTRX
Aug 12, 2026, 4:50 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $10.54
Real-time Price: $9.48 info
Change: -$1.06 (-10%) info
Market Cap: $289.45M info